Physician profile
Karen Wesson
NPI 1023084696
$6,710.76
in general payments reported to CMS, 2019-2025
34 companies · $602 in 2025
The $602 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,692 · 2020: $391 · 2021: $818 · 2022: $825 · 2023: $1,594 · 2024: $789 · 2025: $602.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,886 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,886.08 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $599.54 | 2020-2023 | Xeomin |
| Novartis Pharmaceuticals Corporation | $560.11 | 2019-2025 | |
| Incyte Corporation | $502.89 | 2021-2025 | Opzelura |
| Abbvie INC. | $409.71 | 2019-2025 | Botox |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $404.23 | 2019-2025 | Cabtreo, Jublia |
| E.R. Squibb & Sons, L.L.C. | $394.94 | 2022-2024 | Sotyktu |
| Amgen INC. | $393.95 | 2020-2025 | Otezla, Otezla |
| Lilly USA, LLC | $300.06 | 2019-2024 | Taltz, Olumiant |
| Galderma Laboratories, L.P. | $281.31 | 2019-2025 | Oracea |
| Celgene Corporation | $274.08 | 2019 | |
| Pfizer INC. | $240.47 | 2019-2023 | |
| Janssen Biotech, INC. | $202.99 | 2019-2025 | Tremfya |
| Sun Pharmaceutical Industries INC. | $202.91 | 2019-2025 | Winlevi |
| Mayne Pharma Commercial LLC | $182.37 | 2019-2023 | |
| Epi Health, LLC | $167.77 | 2019-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $166.17 | 2023-2024 | Zoryve |
| Almirall LLC | $164.20 | 2019-2024 | Klisyri, Seysara |
| Allergan, INC. | $151.15 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $148.27 | 2021-2023 | Dupixent |
| Sandoz INC. | $135.57 | 2019-2020 | |
| Genzyme Corporation | $112.56 | 2019-2025 | |
| Leo Pharma INC. | $107.15 | 2019-2021 | |
| Mission Pharmacal Company | $98.27 | 2019-2022 | |
| Dermavant Sciences, INC. | $90.61 | 2023-2024 | Vtama |
| Solta Medical, A Division of Bausch Health US, LLC | $89.25 | 2022-2025 | Clear & Brilliant |
| Dermira, INC. | $75.85 | 2019-2021 | |
| Encore Dermatology INC. | $68.66 | 2019 | |
| Journey Medical Corporation | $43.34 | 2022-2023 | |
| Prugen, INC. Pharmaceuticals | $40.34 | 2019 | |
| Vyne Pharmaceuticals INC. | $25.40 | 2021 | |
| Glenmark Therapeutics INC. | $23.00 | 2019 | |
| Biofrontera INC. | $21.52 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.01 | 2023 | Spevigo |
| Sebela Pharmaceuticals INC. | $14.11 | 2023 | Pramosone, Naftin |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karen Wesson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.